

SICKLE CELL AND THALASSAEMIA STUDY

National Confidential Enquiry into Patient Outcome and Death (NCEPOD)

QUESTIONNAIRE						
CONFIDE	ENTIAL					
Hospital number of patient						
Name of healthcare professional completing questionnaire						
What is this study about? NCEPOD will be collecting data on all haemoglobinopathy patients that die between 1 st January 2005 and 31 st December 2006. The primary aim of the study is to collect information on the care received by haemoglobinopathy patients who die in order to identify remediable factors in the care of these patients. Data will be collected from sites across England, Wales, Northern Ireland, Isle of Man, Guernsey, Defence Secondary Care Agency Hospitals and the Independent Sector.	Who should complete this questionnaire? This questionnaire should be completed by the healthcare professional responsible for the patient's haemoglobinopathy management at the last unit they attended. The unit may be a hospital, a specialist centre or a GP surgery. If the patient did not die at the unit at which they were regularly managed, a questionnaire will also be sent to the healthcare professional responsible for the regular management of the patient.					
Inclusion criteria for this study All patients for whom sickle cell disease (ICD-10	Please return completed questionnaires in the stamped addressed envelope provided.					
D57) or thalassaemia (ICD-10 D56) appears in any part of the diagnosis or cause of death. The study includes both adults and children. Data will be collected on hospital and community-based	How to complete this questionnaire This form will be electronically scanned. Please use a black or blue pen. Please complete all					

CPD accreditation for completing **NCEPOD** Questionnaires

Consultants who complete NCEPOD questionnaires make a valuable contribution to the investigation of patient care. Completion of questionnaires also provides an opportunity for consultants to review their clinical management and undertake a period of personal reflection. These activities have a continuing medical and professional development value for individual Consequently, NCEPOD recommends that consultants consultants who complete NCEPOD questionnaires keep a record of this activity which can be included as evidence of internal / self directed Continuous Professional Development in their appraisal portfolio.

Please do not keep a copy of this questionnaire in the patient notes for legal reasons.

Questions or help

deaths.

If you have any queries about the study or this questionnaire, please contact NCEPOD at sicklecell@ncepod.org.uk or Tel: 020 7631 3444

Thank you for taking the time to complete this questionnaire. The findings of this study will be published in May 2008.

use a black or blue pen. Please complete all sections either in block capitals or a bold cross inside the box provided e.g. Did the patient receive transfusions? ⊠ Yes □ No Unknown If you make a mistake, please "black-out" the box and re-enter the correct information e.g. Did the patient receive transfusions? ⊠ No Unknown Yes Unless indicated, please cross only one box per question. Free space is provided on page 15 for your comments. Incomplete questionnaires may be followed up.

Definitions: Where ^(def) is indicated, a definition is provided on the back of the questionnaire.

WHICH PART TO COMPLETE? • If you were responsible for the patient's regular management and the patient died at your unit (def) -> please complete parts 1, 2 & 3 • If you were responsible for the patient's regular management but they died elsewhere \rightarrow please complete part 1 • If you were responsible for the patient's care at the time of death but not their regular management -> please complete parts 2 & 3 • All complete section A A – THE PATIENT 1. Age at death 2. Male Female Sex 3. Date of death m m PART 1 - THE PATIENT'S REGULAR MANAGEMENT **B – THE PATIENT'S HAEMOGLOBINOPATHY DETAILS** 4. Which haemoglobinopathy did the patient have? Sickle cell anaemia (HbSS) β-thalassaemia major Sickle haemoglobin C (HbSC) β-thalassaemia intermedia Sickle haemoglobin D (HbSD) Other, please specify Sickle β-thalassaemia (HbSβThal) Unknown At what age was the patient first 5. At birth diagnosed as having a haemoglobinopathy? Aged 0-10 years Aged 11-20 years Aged 20+ years Unknown What were the patient's usual haematological values (def)? 6. % Unknown HbS HbF % Unknown b Unknown HbA % HbA2 Unknown % g.dl⁻¹ Total Hb Unknown Unknown Haematocrit % $\times 10^{9} \, J^{-1}$ Unknown White blood cell count FΙ Mean cell volume (MCV) Unknown

7.	WI	nat were the pat	tient's last three ferrit	in values?			
	а	d d	m m y y			μ g .l ⁻¹	Unknown
	b	d d	m m y y			μ g .l ⁻¹	Unknown
	С	d d	m m y y			μ g .l ⁻¹	Unknown
C – F	REG	ULAR MANA	AGEMENT				
8.	а	Did the patient	t receive transfusions	s?	Yes	No	Unknown
	b	there any reco	e give details. Specifi ognised allo-antibodie 0 years/their lifetime sfusion regimen?	es? If known, I	now many un	its were trans	fused to the patient
9.	а	Was the patier	nt taking regular pain		etween crises Yes	?	Unknown
	b	If YES , what re	egular pain medicatio	<u> </u>			se cross ALL that apply)
		,	Opioids	1	Please s		11 37
					Frequenc dose (per		
			NSAIDS	2	Please sp	pecify	
					Frequenc dose (per		
			Paracetamol	3	Frequenc dose (per		
			Other	4	Please sp Frequenc dose (per	cy and	
			Unknown	5			

10.	Was the patient taking folic acid?	Yes No	Unknown
11.	a Was the patient taking prophylactic antibiotics?b If YES,	Yes No	Unknown
	i Please specify antibiotics taken		Unknown
	ii How long had the patient been takin	g antibiotics for?	
		y y m m	Unknown
12.	a Was the patient taking hydroxyurea?	Yes No	Unknown
	b If YES,		
	i What was the daily dosage?	mg/day	Unknown
	ii How long had the patient been takin	g hydroxyurea?	
		y y m m	Unknown
13.	Was the patient taking any other medical	ition?	
		Yes No	Unknown
	b If YES , please specify		
14.	Had the patient received the following vaccin	nations?	
	a Pneumococcal vaccine	Yes No	Unknown
	b Haemophilus influenza type b vaccine	Yes No	Unknown
	c Meningococcal vaccine	Yes No	Unknown
	d Annual influenza vaccine	Yes No	Unknown
D – C	RGANISATION OF REGULAR CAR	E	
15.	Where was the patient regularly managed?	(Please	cross ALL that apply)
		¹ GP surgery	
		Specialist centre (def)	
		Non-specialist hospital ui	nit
	Please specify names of units (def)	_	

16.	a Did the patient attend a haemoglobinopathy outpatient clinic?					
			Ye	s	No	Unknown
	b If YES , how req	gularly?				
			1	Weekly		
			2	Monthly		
			3	Bi-month	ly	
			4	Quarterly	+	
			5	Irregularly	у	
			6	Unknown	l	
17.	In the last year, h specialist hospital u	ow many visits did the unit for haemoglobinopat	patient make thy-related re	e to the G asons?	P surgery, spec	cialist centre or non-
		GP surgery		Visits		Unknown
		Specialist centre		Visits		Unknown
		Non-specialist hospital unit		visits		Unknown
18.	Please provide a contreatment regimen.	commentary on the care	of the patier	nt. Includin	g: the patient's o	compliance with their

PART 2 – FINAL CLINICAL EPISODE

E *	- EXPERIENCE IN MANAGING HAEMOGLOBINOPATHIES (Hospital deaths only)
19.	a What consultant speciality was the patient admitted under?	
	¹ Haematology Plea	ase go to question 20
	² Other, please specify	
	³ Unknown	
	b If the patient was not admitted under a consultant haematologist was the was advice sought from, a consultant haematologist?	patient referred to, or
	¹ Yes, a consultant hae	matologist within this
	hospital Yes, a consultant haem	atologist from another
	hospital/specialist centre No	3 (400)
	4 Unknown	
20.	What was the grade of the most senior doctor to see the patient in their final episo	ode?
		t year 1/2
	² Associate specialist ⁶ SHC	
	³ Staff Grade ⁷ Other	er
	⁴ SpR year 3+ 8 Unk	nown
21.	a Does the most senior doctor involved	
	in the patient's management have a special interest in	Unknown
	haemoglobinopathies?	—
	b If YES, is the most senior doctor a member of the UK Forum on	Unknown
	Haemoglobin Disorders?	
22.	How many haemoglobinopathy patients has the most senior doctor involved in the Sickle cell disea patients	se Unknown
	patient's care managed in the last 12 Thalassaemia patients	Unknown
	·	
23.	. How many years has the most senior doctor involved in the patient's care been involved in the management of Years	Unknown
	haemoglobinopathy patients?	

24.	In your opinion, are there any issu management of haemoglobinopathi		of the medical tear	m/junior doctors in the
	a In this case?	Yes	No	Unknown
	i If YES, please specify			
	b In general?	Yes	No	Unknown
	i If YES, please specify			
F – \$	SEQUENCE OF PATIENT EVE	NTS BEFORE DEATH	1	
25.	Please provide a commentary on Including: presentation, initial diagn continuing care and surgical interve	osis, initial investigations,		
	(See also section H or I if the case i		aternal death.)	
		(Pla	ease continue on ac	ditional sheets if required)

26.	а	Did the patient develop acute che	est syndrome?		
			Yes	No	Unknown
		If YES , please give details of ma and ICU involvement.	nagement. Including: hydr	ation, antibiotics, ti	iming of transfusion
27.	а	Were there any factors in the pat	ient care during this episo	de that could have	affected outcome?
			Yes	No	Unknown
	b	If YES, please specify			
G -		ICAL PATHOLOGY			
28.		at was the patient's cause of deat	th as given on the death ce	ertificate?	
	1.a	-			
	1.b				
	1.c				
	^				
	2	7			
29.		Was an autopsy performed?	Yes	No	Unknown
29.	а	Was an autopsy performed? If YES , was the autopsy consent			Unknown

PLEASE SEND NCEPOD A COPY OF THE AUTOSPY REPORT ON RETURN OF THIS QUESTIONNAIRE

30.		I the patient undergo surgery in the al clinical episode?	Yes Yes	No	Unknown
	lf Y	'ES , please go to section H.			
	If N	IO, please go to section I.			
H *-	МО	RTALITY ASSOCIATED WITH	SURGERY		(Hospital deaths only)
31.	Wł	nat was the operation for and what pro	ocedure was undertaken?		
		More the metions of the Conditate III		<u> </u>	
32.	а	Were the patient's HbS and total Hb values measured pre-operatively?	Yes	No	Unknown
	b	If YES , please specify			
		i HbS		%	Unknown
		ii Total Hb		g.dl ⁻¹	Unknown
33.	а	Did the patient receive any	Yes	No	Unknown
		haemoglobinopathy-specific pre- operative preparation?			
	b	If YES , please provide details. In supplemental oxygen, treatment of	cluding: exchange or top infection and advice from	up transfu a haemato	usion, intravenous fluids, logist/haemoglobinopathy
		team.			
I					

34.	What was the grade of the most senior and	aesth	netist invo	lved in t	the patient's managem	ent?
		1		Consu	Itant	
		2		Associ	ate Specialist	
		3		Staff G	Grade	
		4		SpR ye	ear 3+	
		5		SpR ye	ear 1/2	
		6		SHO		
		7		Other		
		8		Unkno	wn	
35.	How many haemoglobinopathy patients has the most senior anaesthetist involved				Sickle cell disease patients	Unknown
	in the patient's care managed in the last 12 months?				Thalassaemia patients	Unknown
36.	What was the grade of the most senior sur	geoi	n involved	l in the p	patient's management?	,
		1		Consu	Itant	
		2		Associ	ate Specialist	
		3		Staff G	Grade	
		4		SpR ye	ear 3+	
		5		SpR ye	ear 1/2	
		6		SHO		
		7		Other		
		8		Unkno	wn	
37.	How many haemoglobinopathy patients has the most senior surgeon involved in				Sickle cell disease patients	Unknown
	the patient's care managed in the last 12 months?				Thalassaemia patients	Unknown
38.	Was incentive spirometry used post- operatively?			Yes		
	operations.			No		
				Unkno	wn	

39.	Did the patient experience any of the following during the perioperative (def) period?	2	Fever Hypovolaemia
	(Please cross ALL that apply)	3	Hypoxia
		4	Hypercarbia
		5	Acidosis
		6	Low flow state (including use of tourniquet)
		7	Hypothermia
		8	Acute chest syndrome
		9	Sepsis – If YES , which organ(s)?
		10	Other significant complications
			Please specify
			-
40.	a Are there local protocols for the anae	sthetic manag	gement of haemoglobinopathy patients?
		Ye	es
	b If YES , were these protocols followed	1? Y	es
	PLEASE SEND NCEPOD A COPY OF AN	IY PROTOCO	OLS ON RETURN OF THIS QUESTIONNAIRE
l * –	MATERNAL DEATH		(Hospital deaths only)
41.	menstrual period (LMP), expected delive	ery date (EDI	eading up to the patient's death. Including: last D) for gestation; if > 24 weeks was fetus born ertension, cardiac or pulmonary problems in
			(Please continue on additional sheets if required)

42.	what was the grade of the most senior ob	stetrician involved in the patient's management?
		1 Consultant
		² Associate Specialist
		³ Staff Grade
		⁴ SpR year 3+
		⁵ SpR year 1/2
		6 SHO
		Other, please specify
		8 Unknown
43.	How many haemoglobinopathy patients has the most senior obstetrician involved in the patient's care managed in the last 12 months?	Sickle cell disease patients Thalassaemia patients Unknown
44.	How was the baby delivered?	¹ Vaginal delivery
		² Caesarean section
		³ Unknown
45.	Was the patient's HbS value measured during pregnancy?	Yes No Unknown
45.		Yes No Unknown %
45. 46.	measured during pregnancy?	
	 measured during pregnancy? b If YES, please specify a Did the patient receive any change in haemoglobinopathy-specific therapy during pregnancy? b If YES, please provide details. Incl. 	
	 measured during pregnancy? b If YES, please specify a Did the patient receive any change in haemoglobinopathy-specific therapy during pregnancy? b If YES, please provide details. Incl supplemental oxygen, treatment of 	Yes No Unknown uding: exchange or top up transfusion, intravenous fluids,
	 measured during pregnancy? b If YES, please specify a Did the patient receive any change in haemoglobinopathy-specific therapy during pregnancy? b If YES, please provide details. Incl supplemental oxygen, treatment of 	Yes No Unknown uding: exchange or top up transfusion, intravenous fluids,
	 measured during pregnancy? b If YES, please specify a Did the patient receive any change in haemoglobinopathy-specific therapy during pregnancy? b If YES, please provide details. Incl supplemental oxygen, treatment of 	Yes No Unknown uding: exchange or top up transfusion, intravenous fluids,
	 measured during pregnancy? b If YES, please specify a Did the patient receive any change in haemoglobinopathy-specific therapy during pregnancy? b If YES, please provide details. Incl supplemental oxygen, treatment of 	Yes No Unknown uding: exchange or top up transfusion, intravenous fluids,
	 measured during pregnancy? b If YES, please specify a Did the patient receive any change in haemoglobinopathy-specific therapy during pregnancy? b If YES, please provide details. Incl supplemental oxygen, treatment of 	Yes No Unknown uding: exchange or top up transfusion, intravenous fluids,
	 measured during pregnancy? b If YES, please specify a Did the patient receive any change in haemoglobinopathy-specific therapy during pregnancy? b If YES, please provide details. Incl supplemental oxygen, treatment of 	Yes No Unknown uding: exchange or top up transfusion, intravenous fluids,
	 measured during pregnancy? b If YES, please specify a Did the patient receive any change in haemoglobinopathy-specific therapy during pregnancy? b If YES, please provide details. Incl supplemental oxygen, treatment of 	Yes No Unknown uding: exchange or top up transfusion, intravenous fluids,

PART 3 – ORGANISATION OF CARE

,	SUIDELINES		
47.	Does the unit (def) have locally available guiwith the following?	idelines fo	or the management of haemoglobinopathy patients (Please cross ALL that apply)
		1	Pain
		2	Pregnancy
		3	Sequestration crisis
		4	Priapism
		5	Acute anaemia
		6	Acute chest syndrome
		7	Chronic renal failure
		8	General anaesthesia
		9	Iron-chelation therapy
		10	Blood transfusion
		11	Other, please specify
		12	None
48.	Does the unit have separate guidelines for	children a	nd adults?
			Yes No Unknown
	PLEASE SEND NCEPOD A COPY OF ANY	GUIDEL	INES ON RETURN OF THIS QUESTIONNAIRE
K-I	PROVISION OF CARE		
49.	How many haemoglobinopathy patients were cared for at this unit in the year April 2003 – March 2004?		Sickle cell disease patients Thalassaemia patients Unknown Unknown
50.	Is there a dedicated haemoglobinopathy tea	am at the	unit?
		1	Yes, sickle cell disease and thalassaemia team
		2	Yes, sickle cell disease team only
		3	Yes, thalassaemia team only
		4	No If NO , please go to question 57
		5	Unknown

51.	а	regular access to, a haematologist?	No Unknown				
	b	If YES,					
		i How many haematologists are Haematologi there at the unit?	sts Unknown				
		ii What is the total programmed activities (def) in his/her/their job plan for haemoglobinopathies?	l activities Unknown				
52.	а	Does the team include, or is there regular access to, a nurse practitioner?	No Unknown				
	b	b If YES,					
		i How many nurse practitioners are there at the unit?	ioners Unknown				
		ii How many hours a week in total are allocated to haemoglobinopathies?	Unknown				
53.	а	Does the team include, or is there regular access to, a pain specialist (def)?	No Unknown				
	b	If YES,					
		i Is the named pain specialist a doctor or a nurse? Doctor Nurse Other, please specialist a doctor or a nurse? Unknown	ecify				
		ii How many sickle cell disease patients has the named pain specialist managed in the last 12 months? Patients	Unknown				
		How many years has the named pain specialist been involved in managing patients with sickle cell disease? Years	Unknown				
54.		es the team include, or is there regular cess to, an anaesthetic specialist?	No Unknown				
55.		es the team include, or is there regular Yes Seess to, a psychologist?	No Unknown				
56.	а	Does the team include, or is there regular access to, any other services (including ophthalmic, neurology, osteoarticular and renal)?	No Unknown				
	b	If YES , please specify					

57.	Do you have agreed policies with other hospitals for the transfer of haemoglobinopathy patients?								
	Yes No Unknown								
	PLEASE SEND NCEPOD A COPY OF ANY POLICIES ON RETURN OF THIS QUESTIONNAIRE								
58.	Do you have a care pathway for haemoglobinopathy patients at the unit?								
	Yes No Unknown								
PLEASE SEND NCEPOD A COPY OF ANY CARE PATHWAYS ON RETURN OF THIS QUESTIONNAIRE									
59.	. Please write clearly any additional observations you wish to report about the management of this patient								
	Thank you for taking the time to complete this questionnaire								
Or •	return of this questionnaire, please send photocopies of the following: The patient's last six months medical records: GP/specialist centre records and hospital case notes (GP referral letter, medical notes, nursing notes, fluid balance charts and TPR charts) Autopsy report (if available)								
	Only the information requested above should be returned to NCEPOD								

Definitions

TERM	DEFINITION						
Perioperative	The time before, during and after the operative procedure.						
Programmed activity	A scheduled period, nominally equivalent to four hours, during which a consultant undertakes contractual and consequential services.						
Specialist	A healthcare professional with experience in managing haemoglobinopathies.						
Specialist centre	A centre with a dedicated team specialising in the management of haemoglobinopathies.						
Unit	A hospital, GP surgery or specialist centre.						
Usual haematological values	The usual 'steady-state' haematological values of the patient. The values given on the patient's haemoglobinopathy card, if available.						

NCEPOD Epworth House 25 City Road London EC1Y 1AA

FOR NCEPOD USE ONLY										
---------------------	--	--	--	--	--	--	--	--	--	--